EphA2 and EphA3 Maintain Tumour Initiating Cells and are Therapeutic Targets in Brain Cancer

EphA2 和 EphA3 维持肿瘤起始细胞，是脑癌的治疗靶点

• 批准号: nhmrc : 1078893
• 负责人: Dr Bryan Day
• 金额: $ 40.87万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/epha2-epha3-maintain-brain-cancer/518612
• 关键词: EphA2; EphA3; Maintain; Tumour; Initiating

High-grade glioma (HGG) is the most common adult brain cancer; current treatments have increased survival times by months only. Our studies have shown brain cancer specific expression of a family of cell surface proteins called Eph receptors. Furthermore we have shown targeting these receptors with Eph antibodies leads to a significant reduction in brain cancer tumour growth. We now propose to test targeting these receptors in combination to achieve greater responses with minimal side effects.

高级别胶质瘤 (HGG) 是最常见的成人脑癌；目前的治疗仅将生存时间延长了几个月。我们的研究表明，脑癌特异性表达一种称为 Eph 受体的细胞表面蛋白家族。此外，我们还发现，用 Eph 抗体靶向这些受体可显着减少脑癌肿瘤的生长。我们现在建议联合测试这些受体，以实现更大的反应和最小的副作用。